Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ImmunoGen Earns Bayer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ImmunoGen Earns Bayer Milestone

Bayer HealthCare Pharmaceuticals has submitted an IND application for the TAP compound, BAY 94-9343, triggering a $2 million milestone payment to ImmunoGen.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare Pharmaceuticals has submitted an IND application for the TAP compound, BAY 94-9343, triggering a $2 million milestone payment to ImmunoGen. In preclinical testing, BAY 94-9343 demonstrated potent, targeted anticancer activity against mesothelin-expressing tumors.

Bayer is developing BAY 94-9343 under an agreement with ImmunoGen that grants Bayer exclusive rights to use the company’s maytansinoid TAP technology to develop anticancer therapeutics that target mesothelin. ImmunoGen is entitled to receive milestone payments potentially totaling $170.5 million for each resulting product, plus royalties on sales.

“BAY 94-9343 is a promising therapeutic for mesothelin-expressing cancers,” commented Daniel Junius, ImmunoGen president and chief executive officer. “In addition to BAY 94-9343, we expect five other TAP compounds to advance into clinical testing in next 12 months: two developed and wholly owned by ImmunoGen and three through our collaborations with other companies. Overall, we anticipate that there will be 12 TAP compounds in the clinic by this time next year.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters